Mirum Pharmaceuticals, Inc. MIRM Volixibat — Development or regulatory milestones incurred
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:DevelopmentOrRegulatoryMilestonesIncurred.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:28 PM EST
- Fiscal year
- FY2025
- Accession
- 0001759425-26-000013
In April 2024, the Company paid a $10.0 million milestone associated with the approval of Livmarli for the treatment of cholestatic pruritus in patients with PFIC five years of age and older (now twelve months of age and older) by the FDA. In July 2024, the Company paid a $10.0 million milestone associated with the approval of Livmarli for the treatment of PFIC in patients three months and older by the European Medicines Agency. In February 2025, the Company achieved a $5.0 million development milestone related to maralixibat, which was recognized in research and development expense in the accompanying consolidated statements of operations. In addition, as of December 31, 2025, the Company accrued $10.0 million for the achievement of a commercial milestone associated with product sales, which was recognized as an intangible asset in the accompanying consolidated balance sheet as of December 31, 2025. There were no volixibat development and regulatory milestones achieved during the years ended December 31, 2025, 2024 and 2023.
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Mirum Pharmaceuticals, Inc.'s volixibat — development or regulatory milestones incurred?
- Mirum Pharmaceuticals, Inc. (MIRM) reported volixibat — development or regulatory milestones incurred of $0 in Q4 2025.
- What does volixibat — development or regulatory milestones incurred mean?
- Represents the expenses recognized in the financial statements for clinical development or regulatory milestones that have been achieved for the Volixibat program. Unlike cash payments, this metric focuses on the accounting recognition of liabilities or expenses tied to specific R&D progress. It is a critical measure for understanding the timing and impact of development successes on the company's income statement.
Ask your AI about Mirum Pharmaceuticals, Inc.'s volixibat — development or regulatory milestones incurred.
Connect your AI assistant and compare it to peers, right in your chat.
